Introduction {#sec1}
============

Cancer is, in essence, a genetic disease at the cellular level ([@ref129]). However, this consensus was not reached until the groundbreaking discovery of a chromosomal translocation designated the Philadelphia chromosome ([@ref57]). Chromosomal translocation is a unique genetic aberration that can lead to tumorigenesis ([@ref88]). This aberration is a characteristic feature of neoplasia in which a chromosome breaks and a portion is transferred to a different locus. Consequently, the formation of fusion genes, gene disruption or changes in regulatory elements may contribute to the dysregulation or malfunction of the corresponding genes ([@ref105]). Specific chromosomal translocations are associated with distinct subtypes of diseases and have prognostic value. The most extensively studied consequence of rearrangement is the production of oncogenic fusion proteins, such as recurrent mixed lineage leukemia (MLL) fusions with t(11q23), BCR--ABL with t(9;22)(q34;q11), AML1--ETO with t(8;21)(q22;q22) and PML--RARA with t(15;17)(q22;q21) in hematological disorders and EWSR1--FLI1 with t(11;22)(q24;q12), EVT6--NTRK3 with t(12;15)(p13;q25), and EML4--ALK with inv(2)(p21p23) in sarcomas and carcinomas ([@ref15]; [@ref94]). By dysregulating gene expression programs or related signaling pathways, cancerous fusion proteins are causally involved in tumorigenesis. Thus, elucidation of the molecular networks governed by fusion proteins is important to determine the basis of cancer development and to lay the foundation for targeted therapy. One prominent example is the utilization of the kinase inhibitor, imatinib, which specifically inhibits the activity of the recurrent fusion protein BCR--ABL in chronic myeloid leukemia (CML) and changes the natural history of this disease ([@ref29]; [@ref104]).

Due to advances in our knowledge of the complexity of the genome, we now know that non-coding RNAs (ncRNAs), which are transcribed from regions previously known as 'junk' DNA, are functional ([@ref13]; [@ref90]). The non-coding molecules, which include microRNAs (miRNAs), small nucleolar RNAs (snoRNAs), long ncRNAs (lncRNAs), and circular RNAs (circRNAs), have attracted increased attention in cancer research ([@ref33]; [@ref1]). Studies in the last decade have uncovered the strong association between chromosome translocation-driven cancer and ncRNA. Although the most extensively studied ncRNAs in chromosome translocation-associated malignancies are miRNAs, researchers have also begun to focus on other ncRNAs. The ncRNA has been shown to be a critical and indispensable component in fusion protein-driven tumorigenesis. Moreover, ncRNAs might also be directly involved in chromosomal instability by shaping chromosomal translocation or redefining the definition of recurrent fusion transcripts. Thus, the following questions arise: what are the expression signatures of ncRNAs in cancers with chromosomal translocations? What are the causes of these changes? Are these changes irrelevant epiphenomena or are they functionally relevant? What is the relationship between ncRNAs and chromosomal rearrangements? In this review, we will discuss the new advances regarding these questions and their implications for the remaining important questions related to chromosome translocation and ncRNAs. Given that most of the studies on chromosomal rearrangements were related with hematological disorders, ncRNAs in blood malignancies will be the primary focus of this review, but chromosomal rearrangements in solid tumors will be extensively covered.

ncRNA dysregulation is linked to chromosomal translocation {#sec2}
==========================================================

The importance of the regulatory roles of ncRNA has been shown, and ncRNA expression profiling can provide classification, prognostic, and diagnostic information in cancer. Due to the complexity and heterogeneity of various malignancies, miRNAs were proposed as biomarkers a decade ago ([@ref76]) and have shown close correlation with specific cytogenetic abnormalities ([@ref27]; [@ref39]; [@ref68]). For example, *miR-196* was downregulated in patients harboring 11q23 translocations in leukemia, and *miR-21* exhibited higher expression in t(6;11) than in t(9;11) in blood malignancy ([@ref39]). The potential value of miRNAs as diagnostic marker for cytogenetically abnormal acute myeloid leukemia (AML) was further exploited in patient samples with translocations including t(8;21)/*AML--ETO*, inv(16)/*CBFB--MYH1*, t(15;17)/*PML--RARA,* and *MLL* rearrangements (*MLL*-r)*.* Expression signatures involving as few as two (*miR-126/miR-126^\*^*), three (*miR-224*, *miR-368,* and *miR-382*), and seven (*miR-17-5p* and *miR-20a* combined with five miRNAs above) were sufficient to distinguish core-binding factor (CBF), *PML--RARA,* and *MLL*-r leukemias, respectively ([@ref68]). A recent study also showed that miRNAs could distinguish sub-entities such as *MLL*-related t(11;19)(q23;p13.1) and t(11;19)(q23;p13.3) ([@ref4]). Further elucidation of the differences between closely related subtypes will be beneficial for diagnosis and application of targeted therapy.

Systematic expression profiling has also been used to analyze lncRNAs in recent years. We and others reported that lncRNAs were differentially expressed in *MLL*-r and non-*MLL* leukemias or other common rearrangements ([@ref34]; [@ref113]). The specific profiles of subtypes of *MLL*-r, as well as those of infants and elderly patients, were further identified ([@ref34]). Similar results were also found in B-cell acute lymphoblastic leukemia (B-ALL), prostate cancer, and Ewing sarcoma ([@ref101]; [@ref78]; [@ref38]; [@ref40]). A large cohort study of *MLL*-r validated its unique transcriptional landscape ([@ref62]). Notably, the most differentially expressed gene, *LOC100289656*, is a pseudogene, from which an lncRNA is most likely transcribed. The high expression of *LOC100289656* helped identify several cryptic MLL fusions that were previously undetected by standard cytogenetic analyses ([@ref62]). These findings indicate that lncRNAs are a potentially powerful tool to predict minimal residual disease. Notably, *LOC100289656* displayed specific expression patterns in *MLL*-r whereas it displayed no expression or very restricted expression in non-*MLL* leukemia or normal bone marrow and cord and peripheral blood cells. These findings suggest that some lncRNAs may function only in selective genetic contexts, such as chromosome rearrangements.

In addition, snoRNAs and their host genes have attracted renewed attention and have been recognized as new players in cancers ([@ref133]; [@ref80]). Several recent studies reported the general downregulation of a number of snoRNAs in normal hematopoiesis and leukemia ([@ref125]; [@ref103]; [@ref132]). However, AML1--ETO, AML1--ETO9a, and MLL--AF9 enhanced snoRNA expression, and similar results were obtained in t(8;21) patient samples compared with purified CD34^+^ progenitor cells or normal bone marrow ([@ref145]). These findings indicate the unique genetic signatures of malignancies with chromosomal rearrangements. Interestingly, overexpression of the *SNOR112--114* cluster marks acute promyelocytic leukemia (APL) ([@ref125]; [@ref75]). Overexpression of the 14q32 snoRNA transcripts located at the DLK1-DIO3 locus is believed to be related to fusion transcripts harboring the *RARA* gene ([@ref22]). Neither host gene expression nor alternative splicing and mutations accounted for the aberrant expression of snoRNAs ([@ref125]; [@ref132]). Further analyses of the underlying mechanisms are needed. Interestingly, this locus also contains several lncRNAs and 54 miRNAs in addition to the snoRNA cluster. These ncRNAs are upregulated in megakaryopoiesis, and integrated microarray-based analysis suggested that these RNAs might be positive regulators of this process ([@ref113]).

Causes of abnormal expression of ncRNAs in cancers with chromosomal rearrangements {#sec3}
==================================================================================

The altered expression patterns of ncRNAs raised the question of how the ncRNAs are activated or silenced in cytogenetically abnormal cancers and whether their dysregulation is the direct result of chromosomal rearrangements or secondary mutations in cooperation with fusion genes. The expression of ncRNAs is altered in a complex, incompletely understood manner. miRNAs have been shown to be affected by multiple factors, such as chromosomal abnormalities, epigenomics and processing ([@ref10]). Previous studies have also demonstrated the direct involvement of ncRNAs in chromosome breakpoint regions. In this section, we will discuss the underlying mechanisms of the fusion protein-driven and non-fusion protein-driven dysregulation of ncRNAs in cancers with chromosomal rearrangements.

Fusion protein and epigenetic factor-driven transcriptional dysregulation {#sec4}
-------------------------------------------------------------------------

The recurring fusion genes in blood malignancies have been identified as transcriptional regulators in many cases ([@ref15]). In these cases, a dysregulated transcriptional program strongly contributes to tumorigenesis ([@ref15]). The activation or silencing of ncRNAs is believed to be directly controlled by fusion proteins bound to their respective regulatory elements ([Figure 1A](#f1){ref-type="fig"}). For example, in the t(11;16) translocations, *MLL* fuses in-frame with \> 60 partners, which leads to the production of functional fusion proteins ([@ref58]). The N-terminal MLL retains its chromosome-binding domain, while the most common C-terminal partners are nuclear proteins such as AF4, AF9, ENL, and ELL, which are involved in transcriptional activation or elongation ([@ref28]). Thus, the ncRNAs regulated by MLL fusions should be overexpressed. Indeed, a large-scale genome-wide microarray analysis showed that, among 48 miRNAs that were significantly differentially expressed between *MLL* and non-*MLL*-rearranged AML patient samples, 47 of them showed increased expression levels ([@ref68]), suggesting that MLL fusion proteins could promote the transcription of their downstream targets. The upregulated miRNAs between *MLL* and non-*MLL* leukemias are likely directly controlled by MLL chimeras. For example, MLL--AF9 binds to the promoter of *miR-9* and promotes its expression through recruiting the histone H3 lysine 79 (H3K79) methylase DOT1L ([@ref16]). The recruitment of RNA polymerase II and DOT1L-mediated H3K79 methylation is essential for MLL chimeras ([@ref86]; [@ref59]; [@ref32]). The transduction of fusion proteins alone was sufficient to significantly upregulate these ncRNAs ([@ref97]; [@ref84]; [@ref67]; [@ref16]). Consistent with this mechanism, H3K79 methylation was found to be enriched on the promoters of a group of overexpressed lncRNAs in *MLL* leukemia, implying that their activation is directly dependent on fusion proteins ([@ref34]). Similar results were found for other fusion proteins such as AML1--ETO, TEL--AML1, and PML--RARA ([@ref35]; [@ref12]; [@ref108]; [@ref8]; [@ref123]). All these proteins exert repressive transcriptional functions by recruiting epigenetic modification enzymes, such as histone deacetylase (HDAC), nuclear receptor co-repressor 1 (NCOR1), nuclear receptor co-repressor 2 (NCOR2), DNA methyltransferase 1 (DNMT1), and DNA methyltransferase 3A (DNMT3A) ([@ref15]; [@ref47]). In addition to binding to promoters, fusion proteins could also bind distant regulatory elements such as enhancers and regulate the lncRNAs near these regions ([@ref122]) ([Figure 1A](#f1){ref-type="fig"}).

![The causes of the dysregulation of ncRNAs. (**A**) Fusion proteins with transcriptional activity alter the expressions of ncRNAs by directly binding to their regulatory elements and recruiting epigenetic modification enzymes. (**B** and **C**) The dysregulation of ncRNAs is mediated by the downstream effectors of fusion proteins with transcriptional activity or kinase activity. (**D**) The dysregulation of ncRNAs is due to the disturbance of RNA processing/formation process by fusion proteins. (**E**) The loss or amplification of ncRNAs as concomitant mutations. (**F**) The activation or silencing of ncRNA expressions is directly triggered by chromosomal translocation.](mjz080f1){#f1}

Some targets of fusion proteins can also be controlled by the corresponding wild-type counterparts ([@ref97]; [@ref108]; [@ref84]). For example, both wild-type MLL and MLL fusions bound the promoters of *miR-17-92*, and they could reinduce *miR-196b* expression in MLL knockout cells, particularly MLL fusion proteins ([@ref97]; [@ref84]). However, fusion proteins bind a wider range of DNA-target sequences than their wild-type counterpart in some cases ([@ref79]; [@ref108]; [@ref71]). A study focusing on TEL--AML1 found that the majority of promoter regions were specific for fusion proteins and not bound by TEL or AML1 ([@ref71]), indicating that this transcriptional program is unique to the cytogenetically abnormal context. While MLL and MLL fusions have uniformly activating functions ([@ref97]; [@ref84]), fusion proteins and their wild-type counterparts, such as AML1--ETO and AML1, could elicit opposing effects ([@ref3]).

Downstream effectors of fusion proteins control ncRNA dysregulation {#sec5}
-------------------------------------------------------------------

Although fusion proteins with transcriptional activity could directly alter the expression of their targets, some of these proteins might be regulated by the downstream effectors of chimera proteins ([@ref112]; [@ref126]; [@ref51]; [@ref89]) ([Figure 1B](#f1){ref-type="fig"}). For example, *miR-196b* is controlled by HOXA9 ([@ref112]), a pivotal downstream effector of MLL fusion proteins. HOXA9 competes with its antagonist GIF1 for binding sites on *miR-196b* and *miR-21* ([@ref126]). Thus, the activation of *miR-196b* and *miR-21* is dependent on HOXA9 overexpression. This finding also partly explains why the alterations of some ncRNAs are not consistent with the regulatory properties of fusion proteins. For example, *miR-26a* was found to be significantly downregulated in the presence of transcriptional activating oncoproteins, such as MLL fusions ([@ref51]). In fact, *miR-26a* is repressed by MYC, which is promoted by MLL chimeras ([@ref51]). Although the transcriptional promotion of lncRNAs such as *EWSAT1* is dependent on the positive transcriptional regulator EWS--FLI1 fusion in Ewing sarcoma, proximal promoter or more distal enhancer elements binding with fusion protein are not the causes for *EWSAT1* overexpression ([@ref78]). Based on the dependence on chimera proteins, this phenomenon could be due to the dysregulation of downstream targets of fusion proteins, or undetermined properties of oncogenic fusions. This hypothesis was further validated by the enhancement of rRNA transcription by AML1--ETO, which has transcriptionally repressing activity ([@ref3]). By direct binding to rDNA repeats, AML1--ETO activates rRNA transcription instead of silencing this process ([@ref3]). The activation may be due to the enrichment of the hypomethylation marker on the rDNA repeat-binding region of AML1--ETO ([@ref3]). Although MLL fusions are activators, global hypermethylation was observed on the promoters in *MLL*-r infant ALL ([@ref109]), suggesting the involvement of cooperative events. The fusion protein-driven program involves multiple cooperative factors. Thus, the relationships among chimera proteins, epigenetics and ncRNAs remain unclear.

Kinase fusion protein-driven ncRNA dysregulation {#sec6}
------------------------------------------------

Another major group of fusion proteins are chimeras with 'always on' kinase activity ([@ref117]; [@ref93]; [@ref56]). The first chromosomal translocation product ever characterized was BCR--ABL in CML ([@ref88]). New fusion proteins with constitutive kinase activity are continually being discovered ([@ref137]; [@ref49]). The molecular dissection of BCR--ABL could serve as a paradigm for other fusions with kinase activity. The dysregulation of ncRNA expression was shown to be dependent on BCR--ABL ([@ref127]; [@ref9]; [@ref44], [@ref45]; [@ref136]; [@ref20]; [@ref146]). BCR--ABL knockdown or treatment with specific ABL kinase inhibitor, imatinib, reversed the aberrant expression of ncRNAs in a BCR--ABL kinase activity-dependent manner ([@ref127]; [@ref136]; [@ref44]). BCR--ABL cannot directly induce the expression of ncRNAs, and instead exploits downstream signaling pathways or DNA methylation status to manipulate their expression ([Figure 1C](#f1){ref-type="fig"}). The upregulation of *miR-17-92* and lncRNA *H19* was activated by c-MYC, which is a critical downstream target of BCR--ABL signaling in CML ([@ref127]; [@ref44]). Strikingly, *miR-17-92* was downregulated rather than upregulated by BCR--ABL in B-ALL, suggesting various pathways of fusion proteins in different cellular contexts ([@ref110]). Only treatment with inhibitors of BCR--ABL-associated pathways changes the expression of fusion protein-dependent ncRNAs, such as *miR-139-5p* ([@ref20]). A similar phenomenon was observed in other cancers harboring kinase fusion BCR--FGFR1 or ETV6--NTRK3 ([@ref17]; [@ref50]). The DNA methylation status in the upstream regions also contributes to the altered expression patterns of *miR-139-5p*, *miR-203*, and *H19* ([@ref9]; [@ref20]; [@ref146]), which may also be BCR--ABL kinase-dependent. Moreover, fusion proteins as transcriptional regulators might exploit kinase signaling to alter the expression of ncRNAs. For example, the addiction to highly phosphorylated SYK leads to the activation of c-MYC, which in turn stimulates the transcription of lncRNA *MALAT1* in EWS--FLI1-driven multiple myeloma ([@ref118]).

Disturbance of RNA processing machinery by fusion proteins {#sec7}
----------------------------------------------------------

Sporadic reports have suggested that the disturbance of the RNA processing machinery alters ncRNA expression in diseases with chromosomal rearrangements. On the one hand, fusion proteins can block RNA processing ([Figure 1D](#f1){ref-type="fig"}). One study showed that both the MLL fusion and the downstream target MYC directly bound and activated the pri-miR-150 promoter. However, the expression of mature *miR-150* was specifically downregulated in *MLL*-r leukemia ([@ref54]). This downregulation is due to the overexpression of Lin28 by MYC, as Lin28 interferes with the miRNA maturation process ([@ref128]; [@ref54]). On the other hand, fusion proteins can also enhance non-coding ribonucleoprotein (RNP) formation ([Figure 1D](#f1){ref-type="fig"}). As self-renewal is required for leukemogenesis, MLL--AF9 and AML1--ETO enhanced C/D box snoRNA expression ([@ref145]). However, these were not caused by transcriptional activation but by the promotion of small nucleolar ribonucleoprotein (snoRNP) formation ([@ref145]). Suppression of the key formation factor AES led to decreased snoRNA expression ([@ref145]).

Concomitant mutation-induced ncRNA dysregulation {#sec8}
------------------------------------------------

In addition to fusion protein-driven change in ncRNA expression, other co-occurring events facilitate the expression alterations ([Figure 1E](#f1){ref-type="fig"}). More than half of miRNAs are located at minimal regions of loss of heterozygosity (LOHs) and minimal regions of amplification in various cancers ([@ref11]). A 7-Mb fragile region encoding 12% of all miRNAs is frequently lost in specific hematopoietic malignancies ([@ref9]). In addition to direct upregulation by fusion proteins, *miR-17-92* has more than 2-fold amplification at corresponding DNA locus ([@ref84]). This DNA increase could also be found at the regulatory region of ncRNAs. *miR-142* is overexpressed in a subtype of B-cell tumors with t(8;17)(q24;q22) translocation ([@ref61]). Although the translocation involved pri-miR-142, it does not result in upregulation as the pri-miR-142 locus was truncated in the affected allele. Instead, a germline band with increased intensity suggests a gain in the upstream region of pri-miR-142 ([@ref61]). In addition, gain of DNA copies was reported on lncRNAs, such as *PVT1* in PML--RARA-driven APL ([@ref141]).

Notably, some ncRNAs could be directly altered by chromosome rearrangements ([@ref7]; [@ref43]; [@ref111]; [@ref21]) ([Figure 1F](#f1){ref-type="fig"}). These changes might be due to the exchange of upstream regulatory elements of ncRNAs. First, chromosome translocation could activate the expression of ncRNAs. For example, in AML and myelodysplastic syndrome (MDS) cases with t(2;11)(p21;q23), no genes were mapped in this area. Elaborate analyses near the genomic locus revealed the overexpression of *miR-125b-1*, which is sufficient to interfere with primary human CD34^+^ cell differentiation ([@ref7]). In addition to the activation of ncRNAs, silencing upon chromosomal translocation was observed in some regions, such as *miR-29*, which is located near the breakpoint region ([@ref111]).

The multifaceted functions of ncRNAs in fusion protein-driven cancers {#sec9}
=====================================================================

The comprehensive and specific dysregulation of ncRNAs in fusion protein-driven malignancies raises the question whether ncRNAs play indispensable roles or are mere by-products of the genetic alterations. The most extensively studied ncRNAs are miRNAs. miRNAs target RNAs post-transcriptionally by fine-tuning the expression of mRNAs or repressing their translation ([@ref69]). The mode of action for miRNA appears 'simple', as they function in a 'teeterboard' manner: high expression of oncogenic miRNA causes downregulation of tumor suppressors, and low expression of anticancer miRNAs results in upregulation of oncogenic genes ([Figure 2A](#f2){ref-type="fig"}). However, in certain scenarios, miRNAs function in a much more complicated manner. Below are some examples of how miRNA functions in cytogenetically abnormal contexts, which can serve as a paradigm in fusion protein-driven cancers.

![The various modes of actions of ncRNAs in fusion protein-driven cancers. (**A**) The miRNAs function in a teeterboard manner. (**B--E**) The lncRNAs play their roles by regulating translation (**B**), competing for miRNA binding (**C**), recruiting chromatin-remodeling complex (**D**), and binding proteins to regulate gene expressions (**E**). (**F** and **G**) The lncRNAs possibly facilitate AID-dependent gene translocation by transcription opposite to the sense strands (**F**) or bring two translocation partners into close proximity by directing interacting with their DNA loci (**G**). (**H**) Fusion proteins deregulate snoRNA and/or rRNA to exert procancer functions. (**I--K**) The ncRNAs can directly target fusion transcripts (**I**), regulate fusion protein degradation (**J**), or the nucleoplasmic transport of fusion mRNA pathways (**K**).](mjz080f2){#f2}

The functional complexity of miRNAs in a cytogenetically abnormal context {#sec10}
-------------------------------------------------------------------------

As miRNAs usually have multiple targets, defining a certain miRNA as oncogenic or as a tumor suppressor can be difficult in some cases. In fact, miRNAs may target oncogenes and tumor suppressors at the same time. For example, *miR-196b* was shown to delay MLL fusion-driven leukemogenesis in primary bone marrow transplantation (BMT), while accelerating this process in secondary transplantation ([@ref67]). Mechanically, it was found that both oncogenic *HOXA9/MEIS1* and anticancer *FAS* are validated targets of *miR-196b* ([@ref67]). The forced expression of *miR-196b* retarded *MLL* leukemia that is addicted to HOXA9/MEIS1 signaling, while repression of *Fas* led to increased leukemia stem/initiating cells and aggressive disease ([@ref67]; [@ref74]). These results reveal the complexity of miRNA networks in cytogenetically abnormal contexts. This is further supported by another example of *miR-126*. While expression and knockdown of *miR-126* exerted opposing effects in cell lines, both overexpression and knockout of *miR-126* accelerate AML1--ETO leukemogenesis in mouse model. These results may be because overexpression and depletion of *miR-126* have preferential functions in distinct populations of cells *in vivo*. Ectopic expression of *miR-126* induced genes highly expressed in leukemia stem/progenitor cells by silencing *ERRFI1* and *SPRED1*, while *miR-126* depletion activated genes highly expressed in committed progenitor cells by inducing *FZD7* ([@ref66]). Compared with *in vitro* experiments, an *in vivo* study is more likely to provide a full view of the functions of ncRNAs. The discovery of multiple targets of miRNA raises the question of which ones are direct targets of a certain miRNA, especially in regard to non-canonical binding in specific cellular contexts, such as chromosomal translocation. By combining miRNA mimic pull-down and shRNA functional screening, a recent study claimed that *Cdkn1b* (*p27Kip1*) was a genuine target of *miR-196* in the specific *MLL*-rearranged context ([@ref83]). In addition to their cell-intrinsic functions, miRNAs exert their roles in a non-cell intrinsic manner; for example, *miR-125b* induces VEGFA production in MLL--AF9-driven leukemia ([@ref73]). Given that the same family of miRNAs often functions as a cluster, the disruption of multiple homologous miRNAs is sometimes required for effective targeted therapy ([@ref85]). All the examples mentioned above demonstrate that miRNAs actually function in a more complex manner than previously believed.

The diverse functions of lncRNAs and snoRNAs {#sec11}
--------------------------------------------

Unlike the 'teeter board' rules that guide miRNAs, other ncRNAs such as lncRNAs have diverse mechanisms in fusion protein-driven cancer. First, lncRNAs could regulate their adjacent genes by recruiting chromatin-remodeling factors, such as lncRNA *CASC15* in *RUNX1*-rearranged leukemia ([@ref37]) ([Figure 2D](#f2){ref-type="fig"}). Some natural antisense transcripts regulate their sense counterpart via overlapping regions ([Figure 2B](#f2){ref-type="fig"}). For example, *AS-RBM15* enhances the translation of RBM15, a regulator of megakaryocyte differentiation, and both of them are repressed in AML1--ETO leukemia ([@ref123]). In addition to their *cis*-acting effects, lncRNAs could act in *trans* as competing RNAs for miRNAs or binding proteins to regulate gene expression, such as *lncRNA-BGL3* and *EWSAT1* in BCR--ABL and EWS--FLI1-mediated transformations, respectively ([@ref78]; [@ref45]) ([Figure 2C and E](#f2){ref-type="fig"}). Notably, lncRNAs might have direct roles in shaping chromosomal translocations. First, the convergent transcription of the antisense non-coding region and the sense coding region can promote AID-dependent translocation ([@ref98]; [@ref82]; [@ref77]) ([Figure 2F](#f2){ref-type="fig"}). Furthermore, lncRNAs might even demarcate the major breakpoint region as exemplified by *lnc-RP11-211G3.3.1-1* in *BCL-6* breakage ([@ref77]). This lncRNA precisely matches the boundary of the *BCL6* translocation zone ([@ref77]). Another possibility is that lncRNAs might bring two otherwise separate fusion partners into close proximity by mediating long-range intra/interchromosomal interactions ([@ref131]) ([Figure 2G](#f2){ref-type="fig"}). The relationship between lncRNAs and DNA translocation has yet to be validated.

The roles of snoRNAs in cancer have recently been revisited. In cancers with chromosomal rearrangements, snoRNAs function in both canonical and non-canonical manners ([Figure 2H](#f2){ref-type="fig"}). rRNAs are essential for cancer cell proliferation, and studies in AML1--ETO-driven leukemia demonstrated that fusion proteins can either directly activate rRNA transcription or enhance snoRNP formation to catalyze the site-specific 2′-O-methylation of rRNAs ([@ref3]; [@ref145]). The canonical function of C/D box snoRNA in rRNA methylation is required for leukemia self-renewal ([@ref145]). However, snoRNA can also act in a non-canonical manner. For example, *ACA11*, a H/ACA box snoRNA, was shown to regulate ribosomal protein genes by binding a novel non-canonical protein complex in multiple myeloma ([@ref21]). Therefore, the roles of snoRNAs may be more diverse than previously predicted.

circRNAs emerge as new players {#sec12}
------------------------------

Although circRNAs were discovered over two decades ago, the development of next-generation RNA sequencing led to the rediscovery of thousands of circRNAs in eukaryotes ([@ref107]; [@ref81]; [@ref52]; [@ref46]). Importantly, circRNAs are emerging as key regulators in diseases ([@ref100]; [@ref72]). It was reported that circRNAs could be used as biomarkers to distinguish PML--RARA-driven APL with other subtypes of AML ([@ref138]; [@ref64]; [@ref144], [@ref143]). The differential expression patterns suggest that circRNAs might be functional in malignancy with chromosome rearrangements. The proposed roles of circRNAs in cancer include mainly serving as miRNA sponges, interacting with proteins and *cis-*/*trans*-regulation of gene expressions ([@ref5]). However, some reports argued that the majority of circRNAs do not function as miRNA sponges ([@ref46]; [@ref23]). Currently, our understanding on the functions of circRNAs in cancers with chromosome rearrangements is very limited. One experimentally validated example is the formation of oncogenic fusion circRNAs (f-circRNAs) upon chromosome translocation ([@ref42]). Both *PML--RARA* and *MLL--AF9* fusions give rise to more than one f-circRNAs. Although f-circRNAs alone were not sufficient to trigger leukemia, the non-coding f-circRNAs contributed to disease progression *in vivo* when coupled with fusion proteins ([@ref42]). Nevertheless, the mechanism underlying the pathogenetic effects of f-circRNA remains to be uncovered. However, another group failed to detect these f-circRNAs with their home-developed software ([@ref138]). The low abundance of these f-circRNAs and insufficient sequencing depth might result in the failure in computational detection. More efforts are needed to shed light on the roles of circRNAs in cancers with chromosome translocation.

Direct fusion products targeted by ncRNAs {#sec13}
-----------------------------------------

ncRNAs have also been shown to directly regulate fusion products by chromosomal translocation at both RNA and protein levels. First, a group of miRNAs, including *miR-203*, *miR-23a*, *miR-196b*, *miR-30e*, *miR-320a*, and *miR-138*, has been reported to directly target *BCR--ABL* in CML ([@ref9]; [@ref74]; [@ref136]; [@ref134], [@ref135]; [@ref48]) ([Figure 2I](#f2){ref-type="fig"}). Their expression levels are inversely correlated with that of *BCR--ABL*, and their binding sites are on the coding region or 3′UTR of *ABL* ([@ref9]; [@ref74]; [@ref136]; [@ref134], [@ref135]; [@ref48]). Second, the fusion protein products could be regulated by finely controlling their degradation or the nucleocytoplasmic ratio. For example, we showed that *miR-125b* and *HOTAIRM1* target PML--RARA by regulating its autophagic degradation ([@ref18]; [@ref142]) ([Figure 2J](#f2){ref-type="fig"}). Additionally, the forced expression of *miR-1301* trapped *BCR--ABL* mRNA in the nucleus by targeting *RanGAP1*, which is responsible for nuclear protein export ([@ref70]) ([Figure 2K](#f2){ref-type="fig"}).

Fusion proteins can 'connect', 'amplify', and 'switch' ncRNA functions {#sec14}
----------------------------------------------------------------------

In the specific situation of newly formed fusion proteins as the driving force in cancer with chromosomal rearrangements, several unique properties of ncRNA regulation and function are observed. First, fusion products can function as a 'connector' and thus confer context-specific regulation on ncRNAs. As an example, *MALAT1* was downregulated only by MAPK/PI3K inhibitors in EVT6--NTRK3 kinase fusion-positive cell lines ([@ref17]). This finding indicates that the fusion protein could rewire signaling pathways to exploit the functionally relevant lncRNAs. Next, fusion proteins can act as an 'amplifier' to strengthen the functions of ncRNAs. A subtype of aberrantly expressed ncRNAs has no or neglectable effects in normal tissues. However, these ncRNAs could enhance the oncogenic role of fusion proteins or could be essential for fusion protein-driven cancers ([@ref84]; [@ref54]; [@ref16]; [@ref78]). Disruption or overexpression of these ncRNAs exhibits strong phenotypes only in the fusion protein-positive context. Thus, targeting these ncRNAs will not have adverse effects and should be investigated. Finally, the fusion proteins might serve as a 'switcher' to change the pro- or anticancer role of ncRNAs. For example, *miR-9* plays a tumor suppressor role in *EVI1*-induced leukemia as it is repressed by the oncogene *EVI1* ([@ref114]). However, *miR-9* is upregulated in *MLL* leukemia as MLL fusions override the repressive effects of EVI1 and consequently switch its role to a procancer one ([@ref16]). In conclusion, the role of ncRNAs might be entirely different in fusion-protein driven cancer. Thus, the function of ncRNAs should be revisited in these specific contexts.

Non-coding RNAs are directly involved in chromosomal rearrangements {#sec15}
===================================================================

The discovery of chromosomal aberrations has furthered our understanding of tumorigenesis and provided reliable markers for diagnostic and therapeutic purposes. In the traditional view, the primary oncogenic entities in cancers with chromosome rearrangements are fusion proteins. Analysis of the coding products of fusion transcripts remains the focus of research. The universally used criteria for identifying clinically important fusion genes are that the capacity for coding proteins should be retained and the fusion transcripts are not spurious. Since our understanding of the functional genome has expanded to the non-coding genome, our view of fusion genes should be updated to include the non-coding dimension as well. For example, a recent study showed that the overwhelming majority of newly discovered fusion genes are out of frame in non-translocation-related sarcomas ([@ref24]). Thus, the following questions need to be answered: (i) how does chromosomal translocation affect ncRNAs? (ii) Are the coding/non-coding fusion transcripts per se functionally relevant? Recently, several studies have begun to address these questions.

The ncRNA-convergent fusions {#sec16}
----------------------------

The direct interplay between chromosomal translocation and ncRNAs could be roughly summarized in four scenarios. First, more than a decade ago, miRNAs were shown to reside in hot spots for chromosomal abnormalities ([@ref11]). Thus, chromosomal translocation might directly disturb the miRNA locus. The exchange of upstream regions could dysregulate miRNAs without disruption on their sequences ([Figure 3A](#f3){ref-type="fig"}). A prominent example is *miR-125b*, which is frequently fused with the immunoglobulin heavy chain (*IGH*) locus in ALL ([@ref115]; [@ref14]; [@ref121]). The insertion of the *IGH* segment around the miRNA loci activates their expression. Incidental findings also indicate that *miR-29* is deregulated by chromosomal translocation that involves its parental gene *FRA7H* ([@ref111]; [@ref36]). *miR-29* is located in the intron of *FRA7H* and is thus deregulated together with *FRA7H* upon chromosomal translocation. In fact, dysregulation of intron-located small regulatory RNAs might be a paradigm for ncRNAs directly involved in chromosome rearrangements. As the traditional pipeline for discovering fusion genes filters out non-coding and non-recurrent fusion transcripts, this intriguing phenomenon remains unclear. However, a recent study shed light on this issue by searching for both out-of-frame and spurious fusion genes in breast cancer ([@ref95]). The results were enriched for intron-encoded miRNAs, and the change in their upstream elements upregulated the miRNAs regardless of production of functional proteins of the coding regions ([@ref95]; [@ref106]). This phenomenon is not restricted to miRNAs as another class of ncRNA, snoRNAs, is processed from the introns of paternal genes in eukaryotes as well ([@ref30]) ([Figure 3A](#f3){ref-type="fig"}). In multiple myeloma, *WHSC1* is fused with *IGH*, which leads to the overexpression of the former gene. Notably, H/ACA box snoRNA *ACA11* is located in the intron of *WHSC1*, and thus co-expressed with this gene ([@ref21]). The protein product of *WHSC1* is unable to transform wild-type or tumor-prone primary hematopoietic cells, while *ACA11* exerts critical oncogenic role in multiple myeloma cells ([@ref21]). The recurrent inclusion of specific ncRNAs with various 5′ partners redefines the meaning of 'recurrence' of fusion genes. Thus, the functional outcomes may be more important than the structural features of the fusions. These so-called 'ncRNA-convergent fusions' might substantially increase the number of oncogenic fusions.

![ncRNAs are directly involved in chromosome translocation. (**A**) ncRNA-convergent fusions. (**B**) The chromosomal translocation sites reside in the ncRNA regions: production of new ncRNAs by juxtaposition of regulatory elements upstream of non-coding regions or disruption of original ncRNA. (**C**) The fusions of non-coding regions with coding regions lead to the dysregulations of coding products and subsequent alterations of related signaling pathways. (**D**) The coding fusion transcripts or the derived non-coding isoforms, such as circRNAs by back-splicing, function as regulatory RNAs.](mjz080f3){#f3}

The disruption and generation of ncRNAs in breakpoint regions {#sec17}
-------------------------------------------------------------

Although the relationship between other ncRNAs and chromosome fragile sites has not been thoroughly studied, sporadic reports have indicated the close association of lncRNAs with chromosome breakpoint regions. A study detecting fusion transcripts by RNA-Seq in a pan-cancer panel of head and neck squamous cell carcinoma (HNSCC) identified only mRNA- and lncRNA-containing fusions ([@ref6]). This result suggests that the lncRNA locus might contain at least a proportion of chromosome breakpoint regions. Interestingly, a very recent paper stated that lncRNA *FAM230C* and its related genes carry a DNA translocation breakpoint element in their sequences ([@ref25]). One explanation for this is that the genes provide stability for these elements; however, this increases the possibility of DNA breakage and translocation within these lncRNAs. In fact, the second scenario involves the direct disruption of ncRNAs upon chromosomal translocation ([Figure 3B](#f3){ref-type="fig"}). For example, in an orphan disease, MOMO syndrome, the balanced reciprocal translocation found in the patients disrupted a novel lncRNA gene named *LINC00237* ([@ref130]). The patients with MOMO syndrome failed to express this lncRNA. The specific expression pattern of this lncRNA and its strong relationship with MOMO syndrome indicate that it might be functionally relevant in the disease pathogenesis ([@ref130]). These findings can also be extended to snoRNAs as a chromosome break within the *U76* sequence that has been reported in *GAS5--BCL6* fusions ([@ref96]). Whether snoRNA mediates double-stranded DNA break and recombination events is unclear. Furthermore, one study showed that chromosomal translocation could generate new ncRNAs that do not exist in normal tissues ([@ref43]). These results suggest that 'DNA reshuffling' by chromosomal rearrangements can produce novel translocation-specific ncRNAs, which might be filtered out by the current bioinformatics pipeline for fusion protein identification. Although only incidental findings have been reported to date, we believe that future studies will uncover more examples and confirm that the disruptions or generations of ncRNAs upon chromosomal translocations are functionally important events in tumorigenesis.

Non-coding regions partner with coding transcripts {#sec18}
--------------------------------------------------

The third scenario involves the juxtaposition of non-coding regions with protein-coding regions, which change the expression of the protein-coding transcripts instead of resulting in the dysregulation of ncRNAs mentioned above ([Figure 3C](#f3){ref-type="fig"}). This change does not result in a fusion protein because one of the fusion partners is non-coding. Instead, the protein-coding transcripts are dysregulated, which in turn lead to aberrant alterations of downstream signaling ([Figure 3C](#f3){ref-type="fig"}). One such repeatedly reported fusion gene involves *MALAT1* and *GLI1* in epithelioid neoplasm, plexiform fibromyxoma, and gastroblastoma ([@ref116]; [@ref41]; [@ref2]). The high expression of *MALAT1* results in constant activation of *GLI1*, which in turn activates the sonic hedgehog signaling pathway ([@ref116]; [@ref41]). Similar results are also found on double minutes which are small fragments of extrachromosomal DNA observed in many human tumors. Fusion transcripts involving lncRNA *PVT1* and the protein-coding gene *NSMCE2* were identified on double minute chromosomes in AML patients and cell lines ([@ref19]).

The coding/non-coding bifunctional fusion transcripts {#sec19}
-----------------------------------------------------

Along with the increasing investigations of the function of ncRNAs, the distinction between coding and non-coding genes has been slowly blurred. The RNA functions are believed to be Janus-faced because some annotated lncRNAs have been shown to encode small peptides, and some coding RNAs have regulatory functions independent of the proteins they encode ([@ref60]; [@ref92]; [@ref26]). To further complicate this matter, protein-coding genes can also express lncRNA forms by alternative splicing or generate circRNA by back-splicing. [@ref60] designated these bifunctional RNAs as 'cncRNAs' (coding and ncRNA). This finding raises the question of whether the protein-coding fusion transcripts per se have any regulatory functions. Using public t(8;21) AML RNA-Seq and miRNA-Seq data, a study predicted that the recurrent fusion partner *RUNXT1* has a protein-coding-independent function and suggested that this molecule acts as a ceRNA in AML formation ([@ref55]). Moreover, the primary role of fusion cncRNAs might be related to non-coding functions rather than coding functions in some cases. For example, the coding product of the fusion transcript *SLC45A3--ELK4* is unlikely to perturb the protein pool of wild-type ELK4 in prostate cancer, as the abundance of fusion RNA is insufficient ([@ref99]). In fact, *SLC45A3--ELK4* functions as an lncRNA and non-coding mutant transcripts are sufficient to regulate cancer cell proliferation ([@ref99]). In addition to the fusion transcript itself, other fusion ncRNAs, such as circRNA, are derived from the chimeric transcripts upon chromosome translocation. circRNAs are generated by a proactive back-splicing event in which the 3′ tail of one exon is joined to the 5′ head of an upstream exon ([@ref52]). The juxtaposition of otherwise separate genes upon chromosomal translocation results in the close proximity of distant complementary repetitive intronic sequence and thus favors new back-splicing events. This phenomenon is exemplified by the generation of oncogenic fusion circRNA from fusion protein-encoding transcripts both in leukemia and solid tumors ([@ref42]; [@ref120],[@ref119]). Functional analysis revealed that at least some of them are essential for oncogenesis, such as *F-circEA*/*F-circEA-2a*, *F-circM9*, and *F-circPR* in non-small cell lung cancer, *MLL* leukemia, and APL, respectively ([@ref42]; [@ref120],[@ref119]). These findings have challenged the view that the functions of coding transcripts resulting from chromosomal translocations are protein-dependent and add another non-coding layer to their functional complexity ([Figure 3D](#f3){ref-type="fig"}).

Non-coding fusion transcripts as biomarkers {#sec20}
-------------------------------------------

Although the functions of non-coding fusion transcripts remain largely unknown, they have been suggested as diagnostic and prognostic biomarkers. In some scenarios, lncRNA-containing fusions might show a closer relationship to the disease outcome than mRNA fusions, as reported in head and neck cancer ([@ref6]). In contrast to their parental linear fusion RNAs, circRNAs have a circular covalent bond structure that endows them with high resistance to exonuclease digestion ([@ref65]). As circRNAs are enriched and stable in the exosomes of the peripheral blood, several fusion circRNAs have been proposed as liquid pathognomonic markers ([@ref42]; [@ref119]). These molecules may be a good choice when biopsies are difficult to obtain. Notably, chimeric RNAs are not exclusive to cancer, and some fusion RNAs exist in normal conditions because *cis*-splicing or *trans*-splicing at the RNA level can generate fusion transcripts ([@ref53]; [@ref31]). Some fusion RNAs resulting from *cis*-/*trans*-splicing are even identical in malignant and normal cells ([@ref63]; [@ref91]; [@ref101]; [@ref139]). Thus, researchers should be cautious when considering fusion RNAs as biomarkers or drug targets for cancer. Intriguingly, the chimeric transcripts generated at the RNA level might mediate DNA rearrangements, since this is a process that occurs in lower species ([@ref63]; [@ref140]; [@ref53]). Chimeric RNA might serve as template for double-stranded DNA breakage repair or as a scaffold to bring two genomic loci into proximity to induce chromosomal rearrangements, thereby producing DNA translocation-triggered fusion transcripts ([@ref53]; [@ref31]). Alternatively, there might be no causal relationship between chimeric RNA generated by *trans*-splicing and chromosomal translocation. Instead, same factors might contribute to both *trans*-spliced RNA chimeras and DNA rearrangements, which could bring the separate gene loci into close proximity.

Perspective {#sec21}
===========

Researches in the past decade suggested a direct link between chromosome translocation-driven cancer and ncRNAs. Although miRNAs are the best-studied ncRNAs in cytogenetically abnormal contexts, research focus has started to move to other ncRNAs, such as lncRNAs, circRNAs, and snoRNAs. However, the expression patterns and functions of these novel molecules in distinct subtypes of cancers with chromosomal rearrangements, especially solid tumors, are unclear. Hence, more efforts are needed to determine the profiles of these ncRNAs. Notably, several ncRNAs function only in malignancies with chromosomal rearrangements and are dispensable in normal conditions; thus, these molecules should be assessed as potential therapeutic targets. Given that direct targeting of ncRNAs is not applicable in the clinic, identification of targets in upstream pathways that control the expression of ncRNAs is needed. Thus, further elucidation of the complicated mechanisms underlying ncRNA regulation in cancers with chromosomal rearrangements is important.

In addition, the direct involvement of ncRNAs in the formation of fusion transcripts and regulation of chromosomal translocation requires further analyses. Although several studies have reported the existence of non-coding fusion transcripts, whether they are functional remains largely elusive. Determination of whether ncRNAs influence the formation of chromosomal rearrangements and the underlying mechanisms is also necessary. Based on the current findings, the transcription of ncRNAs or ncRNAs themselves should be taken into account when addressing how DNA translocations are formed. However, more experimental evidence is needed to validate this concept. Further analysis of ncRNAs may help determine the preferential regions of chromosomal translocation and provide explanations for this process.
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